Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Bissonnette

Showing results (111-120 of 222) with videos related to

Pageof 23
Sort By:
Dermatology and Therapy|August 6, 2022
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b TrialMelinda J Gooderham, Giampiero Girolomoni, Julian O Moore, et al.
Journal of the American Academy of Dermatology|December 28, 2006
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005Lasse R Braathen, Rolf-Markus Szeimies, Nicole Basset-Seguin, et al.
The Journal of Dermatological Treatment|January 16, 2016
A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasisRobert Bissonnette, Monica Luchi, Rosanne Fidelus-Gort, et al.
The Journal of Allergy and Clinical Immunology|October 22, 2021
Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasisPatrick Baum, Sudha Visvanathan, Sandra Garcet, et al.
European Journal of Immunology|June 19, 2025
Tissue-Resident Memory and Follicular/Peripheral Helper PD-1<sup>+</sup> T Cells Infiltrate Lesional Skin in Atopic DermatitisHeena Mehta, Léane Pellerin, Manuel Rubio, et al.
JAMA Dermatology|October 3, 2019
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical TrialMelinda J Gooderham, Seth B Forman, Robert Bissonnette, et al.
The New England Journal of Medicine|July 9, 2015
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque PsoriasisKenneth B Gordon, Kristina Callis Duffin, Robert Bissonnette, et al.
Dermatology and Therapy|March 4, 2021
Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot StudyUlrich Mrowietz, A David Burden, Andreas Pinter, et al.
JAMA Dermatology|May 12, 2021
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical TrialsJonathan I Silverberg, Eric L Simpson, Andreas Wollenberg, et al.
The Journal of Dermatological Treatment|July 15, 2025
The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trialRobert Bissonnette, Ronald Vender, Andreas Pinter, et al.
Pageof 23

Showing results (111-120 of 222) with videos related to

Sort By:
Pageof 23
Dermatology and Therapy|August 6, 2022
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b TrialMelinda J Gooderham, Giampiero Girolomoni, Julian O Moore, et al.
Journal of the American Academy of Dermatology|December 28, 2006
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005Lasse R Braathen, Rolf-Markus Szeimies, Nicole Basset-Seguin, et al.
The Journal of Dermatological Treatment|January 16, 2016
A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasisRobert Bissonnette, Monica Luchi, Rosanne Fidelus-Gort, et al.
The Journal of Allergy and Clinical Immunology|October 22, 2021
Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasisPatrick Baum, Sudha Visvanathan, Sandra Garcet, et al.
European Journal of Immunology|June 19, 2025
Tissue-Resident Memory and Follicular/Peripheral Helper PD-1<sup>+</sup> T Cells Infiltrate Lesional Skin in Atopic DermatitisHeena Mehta, Léane Pellerin, Manuel Rubio, et al.
JAMA Dermatology|October 3, 2019
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical TrialMelinda J Gooderham, Seth B Forman, Robert Bissonnette, et al.
The New England Journal of Medicine|July 9, 2015
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque PsoriasisKenneth B Gordon, Kristina Callis Duffin, Robert Bissonnette, et al.
Dermatology and Therapy|March 4, 2021
Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot StudyUlrich Mrowietz, A David Burden, Andreas Pinter, et al.
JAMA Dermatology|May 12, 2021
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical TrialsJonathan I Silverberg, Eric L Simpson, Andreas Wollenberg, et al.
The Journal of Dermatological Treatment|July 15, 2025
The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trialRobert Bissonnette, Ronald Vender, Andreas Pinter, et al.
Pageof 23